The invention relates to the use of ex vivo expanded tumor-infiltrating lymphocytes (TILs) as a potential treatment modality for cancer. It further details compositions of these TILs between patients and how this relates to prognosis and methods for improving TIL expansion and function for the treatment of cancer. We have identified a novel regulatory cell type, innate lymphoid cells (ILC), that appear to impact TILs. Specifically, administering to the patient a therapeutically effective amount of a compound that decreases the suppressive effect of ILCs can have an impact on tumor infiltrating lymphocyte (TIL) propagation, expansion or function. Rahbar Rahimpour rahbar.rahimpour@uhnresearch.ca 416-581-7728
Smart, interactive desk
May 8, 2023
No Comments
Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the